2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 86

Age Dependent Effects of Cholesterol and Smoking on the Risk of Rheumatoid Arthritis in Women – Results from a Nested Case Control Study
Abstract Number: 1873

Age- and Cause-Specific Standardized Mortality Ratio of Systemic Lupus Erythematosus Patients in Ontario, Canada over 43 Years (1971-2013)
Abstract Number: 2675

Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Abstract Number: 2908

Agreement between Ultrasound and Whole Body Magnetic Resonance Imaging Assessment of Joint Inflammation and Enthesitis in Rheumatoid Arthritis Patients
Abstract Number: 2819

Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
Abstract Number: 1044

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model
Abstract Number: 492

All Site Cancers and Lymphoma Incidence in US Veterans with Rheumatoid Arthritis 2001-2015
Abstract Number: 2132

All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
Abstract Number: 39

Allogeneic Mesenchymal Stem Cells Derived Extracellular Vesicles As a Superior Immunosuppressant in Murine Arthritis Therapy
Abstract Number: 2969

Allopurinol Dose Escalation Slows Progression of CT Bone Erosion in People with Gout: Imaging Sub-Study of a Randomized Control Trial
Abstract Number: 136

Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity
Abstract Number: 975

Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
Abstract Number: 1732

Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
Abstract Number: 2057

Alterations of the Splicing Machinery in Leukocyte Subsets of Rheumatoid Arthritis Patients Modulate Their Inflammatory, Autoimmune and Atherothrombotic Profiles
Abstract Number: 1941

Altered Cognitive Function in Systemic Lupus Erythematosus and Associations with Inflammation and Functional Brain Changes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].